Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026 [Yahoo! Finance]
Beyond Air, Inc. (XAIR)
Company Research
Source: Yahoo! Finance
Received US patent allowance covering proprietary gas delivery technology for UNO GARDEN CITY, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced updated follow-up data from its Phase 1 UNO trial, which are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, California. The Phase 1 trial (NCT05351502) was a clinical proof-of-concept trial that assessed the intratumoral administration of UNO in patients with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic lesions. The trial enrolled ten heavily pretreated patients, including breast cancer (n=6), squamous cell carcinoma (n=2), and melanoma (n=2). Patients received a median of 4 prior systemic therapies and 11 total ca
Show less
Read more
Impact Snapshot
Event Time:
XAIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XAIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XAIR alerts
High impacting Beyond Air, Inc. news events
Weekly update
A roundup of the hottest topics
XAIR
News
- Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026GlobeNewswire
- Beyond Air to Participate in the D. Boral Capital Global Conference 2026GlobeNewswire
- Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (GPO)GlobeNewswire
- Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.MarketBeat
- Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO [Yahoo! Finance]Yahoo! Finance
XAIR
Earnings
- 8/12/25 - Miss
XAIR
Sec Filings
- 4/15/26 - Form 8-K
- 4/10/26 - Form 8-K
- 4/1/26 - Form 8-K
- XAIR's page on the SEC website